Skip to content
The Policy VaultThe Policy Vault

Intrarosa (prasterone)United Healthcare

moderate to severe dyspareunia due to vulvar and vaginal atrophy (VVA) due to menopause

Preferred products

  • Imvexxy (estradiol)
  • Osphena (ospemifene)
  • Premarin vaginal cream

Initial criteria

  • Diagnosis of moderate to severe dyspareunia
  • AND Patient has vulvar and vaginal atrophy due to menopause
  • AND History of failure, contraindication, or intolerance to two of the following: Imvexxy (estradiol) OR Osphena (ospemifene) OR Premarin vaginal cream

Reauthorization criteria

  • Documentation of positive clinical response to therapy

Approval duration

12 months